[go: up one dir, main page]

MX2018010866A - Tratamiento de pacientes con trasplante de celulas madre hematopoyeticas. - Google Patents

Tratamiento de pacientes con trasplante de celulas madre hematopoyeticas.

Info

Publication number
MX2018010866A
MX2018010866A MX2018010866A MX2018010866A MX2018010866A MX 2018010866 A MX2018010866 A MX 2018010866A MX 2018010866 A MX2018010866 A MX 2018010866A MX 2018010866 A MX2018010866 A MX 2018010866A MX 2018010866 A MX2018010866 A MX 2018010866A
Authority
MX
Mexico
Prior art keywords
cell transplantation
hematopoyetic
patients
treatment
mother cell
Prior art date
Application number
MX2018010866A
Other languages
English (en)
Other versions
MX392530B (es
Inventor
Bucher Christoph
Gergely Peter
Katopodis Andreas
Smith Philip
Original Assignee
Kyorin Seiyaku Kk
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kyorin Seiyaku Kk filed Critical Kyorin Seiyaku Kk
Publication of MX2018010866A publication Critical patent/MX2018010866A/es
Publication of MX392530B publication Critical patent/MX392530B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Steroid Compounds (AREA)
  • Prostheses (AREA)

Abstract

La presente invención se refiere a un método para acelerar el injerto de células madre en un paciente con la necesidad de trasplante células madre hematopoyéticas.
MX2018010866A 2016-03-08 2017-03-06 Aceleramiento del injerto de pacientes con trasplante MX392530B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662305003P 2016-03-08 2016-03-08
PCT/IB2017/051291 WO2017153889A1 (en) 2016-03-08 2017-03-06 Treatment of hematopoietic stem cell transplant patients

Publications (2)

Publication Number Publication Date
MX2018010866A true MX2018010866A (es) 2018-11-29
MX392530B MX392530B (es) 2025-03-24

Family

ID=58358777

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2018010866A MX392530B (es) 2016-03-08 2017-03-06 Aceleramiento del injerto de pacientes con trasplante

Country Status (13)

Country Link
US (2) US20190022033A1 (es)
EP (1) EP3426279B1 (es)
JP (2) JP6906154B2 (es)
KR (1) KR20180119593A (es)
CN (1) CN108778310B (es)
AU (1) AU2017231000B2 (es)
BR (1) BR112018017134A2 (es)
CA (1) CA3015755C (es)
EA (1) EA039817B1 (es)
ES (1) ES2917208T3 (es)
MX (1) MX392530B (es)
TW (2) TWI731944B (es)
WO (1) WO2017153889A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7389486B2 (ja) * 2018-07-27 2023-11-30 プリオセラ リミテッド 造血幹細胞移植を受けた患者における血液悪性腫瘍の再発抑制剤

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2873181T3 (es) * 2013-02-20 2021-11-03 Priothera Ltd Tratamiento de la enfermedad de injerto contra huésped en pacientes trasplantados

Also Published As

Publication number Publication date
MX392530B (es) 2025-03-24
AU2017231000B2 (en) 2023-06-29
AU2017231000A1 (en) 2018-08-16
EP3426279A1 (en) 2019-01-16
KR20180119593A (ko) 2018-11-02
TW202139994A (zh) 2021-11-01
EP3426279B1 (en) 2022-05-04
CA3015755A1 (en) 2017-09-14
JP2019507782A (ja) 2019-03-22
WO2017153889A1 (en) 2017-09-14
CA3015755C (en) 2024-01-30
US20210346317A1 (en) 2021-11-11
JP2021130679A (ja) 2021-09-09
CN108778310A (zh) 2018-11-09
BR112018017134A2 (pt) 2019-01-15
JP6906154B2 (ja) 2021-07-21
ES2917208T3 (es) 2022-07-07
EA039817B1 (ru) 2022-03-16
EA201891996A1 (ru) 2019-02-28
TW201733594A (zh) 2017-10-01
CN108778310B (zh) 2022-08-19
TWI810555B (zh) 2023-08-01
US20190022033A1 (en) 2019-01-24
TWI731944B (zh) 2021-07-01
JP7245548B2 (ja) 2023-03-24

Similar Documents

Publication Publication Date Title
MX370018B (es) Metodos mejorados para la elaboracion de terapias celulares adoptivas.
CO2018004937A2 (es) Células asesinas naturales y células ilc3 y usos de las mismas
EP4403138A3 (en) Device and method with reduced pacemaker rate in heart valve replacement
CL2018001258A1 (es) Métodos para tratar las condiciones asociadas con la activación del complemento dependiente de masp-2
MX2020011254A (es) Celulas t car anti-bcma para agotamiento de celulas de plasma.
MX2017002382A (es) Metodos para tratar el mieloma multiple con compuestos imunomodulares en combinacion con anticuerpos.
BR112017017886A2 (pt) gerando populações de células endoteliais arteriais
CL2017003456A1 (es) Metodos para tratar tumores de celulas epitelioides
BR112017012335A2 (pt) método, dispositivo e kit para a cultura em massa de células usando uma membrana de poli-imida porosa
MX2017004580A (es) Combinaciones de auristatina sinergica.
BR112017001550A2 (pt) enxerto de tecido
CR20150543A (es) Método de tratamiento de páncreas e hígado para condiciones por transplante de células madre en paredes de conducto biliar
EA201890442A1 (ru) Получение фоторецепторов для лечения заболеваний сетчатки
CL2015001446A1 (es) Procedimiento de preparación de albumina humana con nivel de oxigeno disuelto reducido.
AR108134A1 (es) Diferenciación de células madre pluripotentes en células del endodermo del intestino medio
SG11201806177QA (en) Transplant material for treatment of heart disease
MX2022014077A (es) Formulaciones y metodos para tratar organismos fotosinteticos y mejorar las calidades y cantidades de los rendimientos con formulaciones de compuestos de glicano.
UY35438A (es) Procedimiento para preparar inhibidores de la glucosilceramida sintasa.
BR112017020513A2 (pt) método de produção de peixe para transplante, peixe para transplante, método de produção de espécie híbrida de peixe e espécie híbrida de peixe
BR112019000837A2 (pt) células miméticas de célula b
DK3189844T3 (da) Pluripotent stamcelle til behandling af diabetisk hudsår
MX2015012341A (es) Enriquecimiento de células tumorales circulantes por desgaste de glóbulos blancos.
MX395106B (es) Celulas t alogenicas específicas de wt1 y usos de las mismas.
MX2016014718A (es) Cocultivo de propionibacteria y levadura.
DK3573631T3 (da) Fækal mikrobiota til behandling af patienter med en transplantation af hæmatopoietiske stamceller